ICPT Intercept Pharmaceuticals Inc

Price (delayed)

$17.13

Market cap

$568.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.14

Enterprise value

$990.87M

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded ...

Highlights
The EPS has soared by 50% year-on-year and by 24% since the previous quarter
The net income has grown by 50% year-on-year and by 23% since the previous quarter
The quick ratio has declined by 9% year-on-year but it is up by 2.2% since the previous quarter
The equity has plunged by 158% YoY
ICPT's debt is up by 5% year-on-year

Key stats

What are the main financial stats of ICPT
Market
Shares outstanding
33.2M
Market cap
$568.74M
Enterprise value
$990.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
Earnings
Revenue
$341.03M
EBIT
-$120.78M
EBITDA
-$111.6M
Free cash flow
-$110.21M
Per share
EPS
-$5.14
Free cash flow per share
-$3.32
Book value per share
-$6.13
Revenue per share
$10.28
TBVPS
$15.77
Balance sheet
Total assets
$523.22M
Total liabilities
$726.42M
Debt
$575.82M
Equity
-$203.2M
Working capital
$347.82M
Liquidity
Debt to equity
-2.83
Current ratio
3.39
Quick ratio
3.22
Net debt/EBITDA
-3.78
Margins
EBITDA margin
-32.7%
Gross margin
98.8%
Net margin
-49.9%
Operating margin
-36.5%
Efficiency
Return on assets
-30.7%
Return on equity
N/A
Return on invested capital
-13.9%
Return on capital employed
-32%
Return on sales
-35.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ICPT stock price

How has the Intercept Pharmaceuticals stock price performed over time
Intraday
1.36%
1 week
1.84%
1 month
9.32%
1 year
-41.44%
YTD
-30.65%
QTD
15.35%

Financial performance

How have Intercept Pharmaceuticals's revenue and profit performed over time
Revenue
$341.03M
Gross profit
$337.01M
Operating income
-$124.35M
Net income
-$170.13M
Gross margin
98.8%
Net margin
-49.9%
Intercept Pharmaceuticals's operating margin has surged by 66% YoY and by 34% QoQ
Intercept Pharmaceuticals's operating income has surged by 59% YoY and by 30% QoQ
ICPT's net margin has soared by 58% year-on-year and by 28% since the previous quarter
The net income has grown by 50% year-on-year and by 23% since the previous quarter

Growth

What is Intercept Pharmaceuticals's growth rate over time

Valuation

What is Intercept Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
1.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
The EPS has soared by 50% year-on-year and by 24% since the previous quarter
The equity has plunged by 158% YoY
ICPT's price to sales (P/S) is 92% lower than its 5-year quarterly average of 20.0 and 42% lower than its last 4 quarters average of 2.9
ICPT's revenue is up by 20% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Intercept Pharmaceuticals business performance
The ROS has soared by 66% year-on-year and by 34% since the previous quarter
Intercept Pharmaceuticals's return on invested capital has surged by 51% YoY and by 27% QoQ
Intercept Pharmaceuticals's return on assets has increased by 35% YoY and by 20% QoQ

Dividends

What is ICPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ICPT.

Financial health

How did Intercept Pharmaceuticals financials performed over time
The total assets is 28% smaller than the total liabilities
The total assets has declined by 18% year-on-year
Intercept Pharmaceuticals's current ratio has decreased by 9% YoY
The equity has plunged by 158% YoY
Intercept Pharmaceuticals's debt to equity has surged by 59% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.